Pfizer vaccine allergy rates in the US were higher than expected

Washington, Ta. Thursday, December 24, 2020

On the one hand, the United States has struck a deal with Pfizer to obtain another 100 million doses of its Corona vaccine, which has sparked renewed debate over the issue.

Discussions are currently underway between vaccine maker Pfizer and the National Institutes of Health to conduct a clinical trial of those with more allergies. Munsif Slau, chief scientific adviser at Operation Rap Speed, said the amount of reactions that have occurred since Dec. 22 appears to be higher than other vaccines.

On this issue, UK regulators have issued an advisory that those who have an allergic reaction should not be vaccinated with Pfizer-Bioentech. The two regulators were alerted to the matter by UK regulator MHRA following the reaction of the two health workers.

MHRA's Chief Executive Dr. Jun Rene testified before a parliamentary committee that the intensive clinical trial did not mention cases of allergic reactions. Advice on what to do in this matter needs to be delivered to Melvi Field immediately.